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Melanoma Cells Control HA Synthesis in
Peritumoral Fibroblasts via PDGF-AA and
PDGF-CC: Impact on Melanoma Cell Proliferation
Anja Willenberg1, Anja Saalbach1, Jan C. Simon1,2 and Ulf Anderegg1,2
The microenvironment surrounding tumors has an important role in tumor progression. Fibroblasts (Fbs) of the
tumor stroma receive signals from tumors and transform the extracellular matrix, thus supporting tumor
growth, motility, and metastasis. The matrix component hyaluronan (HA) has a pivotal role in tumor
progression. Here we analyzed the cell populations that synthesize HA in human malignant melanoma (MM)
cells and studied the regulatory network between MM cells and stromal Fbs controlling HA synthesis. Tissue
analysis indicated that Fbs are the main source of HA in the stroma of melanoma, whereas MM themselves
synthesize only minute amounts of HA. In vitro, Fb-derived HA is mainly produced by hyaluronan synthase
2 (HAS2) and enhances proliferation of MM. Proteins secreted by MM can further increase HA synthesis in Fbs
in a phosphatidylinositol 3/mitogen-activated protein-kinase-dependent manner. Melanoma cell–derived
platelet-derived growth factor (PDGF)-AA and PDGF-CC were identified as major mediators that signal through
PDGFR-a and thus induce HAS2-mediated HA synthesis in Fbs. In conclusion, we have identified a complex
interaction of MM with its surrounding microenvironment by demonstrating that MM by the release of
PDGF-AA and PDGF-CC upregulate HA synthesis in Fbs, which in turn stimulates MM proliferation in a
paracrine manner.
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INTRODUCTION
Tumor–stroma interactions have a pivotal role in cancer
biology. The tissue microenvironment surrounding the tumor,
especially cancer-associated fibroblasts (Fbs) in the stroma of
solid tumors, supports tumor growth, motility, and metastasis
(Kalluri and Zeisberg, 2006; Ostman and Augsten, 2009).
Malignant melanoma cells (MM) activate Fbs to release
increased amounts of metalloproteinases, glycosaminogly-
cans, and cytokines, thereby transforming the extracellular
matrix to support tumor progression (Wandel et al., 2000;
Loffek et al., 2005; Zigrino et al., 2005, 2009).
The glycosaminoglycan hyaluronan (HA), a high molecu-
lar unbranched polymer of repeating disaccharides of glu-
curonic acid and N-acetylglucosamine, seems to have a
crucial role in tumor growth and metastasis (Toole, 2002).
HA is synthesized by three different HA synthases (HASs),
namely HAS1, HAS2, and HAS3, which are located at the
inner side of the plasma membrane (Weigel et al., 1997;
Tammi et al., 2002). The synthases differ in their enzymatic
properties concerning HA elongation rate, enzymatic activ-
ity, and Km-value for the substrates (Itano et al., 1999).
Enzymatic degradation of HA is performed by hyaluronidases
when high-molecular-weight HA is cleaved by Hyal-2 and
the resulting 20 kDa fragments are further processed intraly-
sosomally by hyaluronidase-1 (Stern, 2003; Stern et al.,
2006). The importance of HA for tumor progression has been
demonstrated for many solid tumors, including breast cancer
(Auvinen et al., 1997; Bose and Masellis, 2005), colon
carcinoma (Misra et al., 2008), and ovarian cancer (Tammi
et al., 2008). Tumors with an HA-rich stroma have a growth
advantage compared with those without (Tammi et al., 2008).
HA promotes angiogenesis (Itano et al., 2008), modulates
antitumor response by immobilization of inflammatory cells
(Day and de la Motte, 2005; Itano and Kimata, 2008),
supports tumor cell motility (Afify et al., 2009), and enhances
proliferation (Ahrens et al., 2001; Itano et al., 2008).
It has been shown before that MM supernatants stimulate
HA synthesis in dermal Fbs (Knudson et al., 1984; Merrilees
and Finlay, 1985; Godden et al., 1999; Edward, 2001) and
various MM-derived paracrine mediators have been ana-
lyzed. However, the mechanisms of HA synthesis and the
contribution of the enzymes of the HA metabolism are still
unknown. In this paper we compared the HA metabolism in
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human Fbs and MM and analyzed cell lines with regard to
their expression of individual HAS enzymes and their impact
on HA release by MM-exposed Fbs. We show that Fbs are the
major source of HA. Moreover, we confirmed that HAS1 and
HAS2 in Fbs are regulated by MM-derived mediators and
demonstrate that MM-derived PDGF-AA and PDGF-CC
stimulate HAS2 expression in Fbs via PDGFR-a and thus
augment HA deposition by Fbs, thus substantiating previous
data from Godden et al. (1999). The HA synthesized by
activated dermal Fbs enhanced proliferation of MM in vitro,
suggesting that also in vivo stromal HA deposited on
paracrine control of MM-derived soluble mediators might
contribute to melanoma progression.
RESULTS
Stromal Fbs surrounding melanomas are the main producers of
HA in vivo and in vitro
To identify HA-synthesizing cell types in MM, immuno-
affinity stainings with biotinylated HA binding protein (HAbP)
of melanoma specimen were performed. HA was detected
predominantly in the tumor stroma (Figure 1a and b). Using
double staining with an Fb-specific antibody (Saalbach et al.,
1997) we found predominant colocalization of HA and Fbs
(Figure 1c). MM themselves clearly showed weaker HA
staining (Figure 1a–d).
In vitro, basal HA synthesis was analyzed in cultured
dermal Fbs and MM by ELISA. Fbs released over a thousand
times more HA into the culture supernatants compared
with identical numbers of MM (Figure 1e). In accordance,
HAS2–mRNA was significantly stronger expressed in Fbs than
in MM as detected by quantitative reverse transcription (RT)-
PCR (Figure 1f). HAS2 represents the main HA-synthesizing
enzyme in resting Fbs (Averbeck et al., 2007). HAS1– and
HAS3–mRNA were only expressed at low levels in all cell
types (data not shown).
MM proliferation is increased by Fb-conditioned culture
supernatants, depending on Fb-derived HA and soluble
mediators from MM further stimulate HA-synthesis in Fbs
In medium transfer experiments we tested whether MM
benefit from Fb-derived HA and observed a significantly
increased proliferation rate of MM growing in Fb-conditioned
medium (Fb-CM; Figure 2a). When HA synthesis in Fbs was
inhibited by 70–90% (Figure 2b) by silencing of HAS2, the
proliferation rate of MM decreased markedly (Figure 2a), thus
suggesting proproliferative effects of Fb-derived HA.
Next we studied the influence of MM-derived soluble
factors on the HA synthesis in Fbs. Fbs were incubated with
CM (melanoma cell–conditioned medium, MM-CM) of
different melanoma cell lines. Bro- and HT144-CM induced
a significant increase of HAS1– and HAS2–mRNA expression
in Fbs compared with control, whereas A375-CM did not
(Figure 2c and d). No changes in the HAS3–mRNA expression
were induced by any of the CM (data not shown).
Consequently, HA release by Fbs was significantly increased
after 24 hours of stimulation with Bro- or HT144-CM and not
affected significantly by A375-CM (Figure 2e), suggesting a
lower inductive capacity of the latter cell line. Incubation of
MM with Fb-CM did not modify low HA synthesis of MM
(data not shown).
To identify melanoma-derived soluble mediators that
stimulate HA synthesis in Fbs, we tested whether lactate, a
known inducer of HA (Stern et al., 2002; Rudrabhatla et al.,
2006), or soluble proteins stimulate HA production. First,
lactate concentrations in supernatants of MM with different
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Figure 1. Hyaluronan (HA) and hyaluronan synthase 2 (HAS2)–mRNA are
predominantly expressed by stroma cells in vivo and in vitro. HA in
malignant melanoma (MM) is deposited mainly in the fibroblast-rich stroma.
(a–d) A superficially spreading melanoma (Clark III, Breslow 1.2mm) is
shown. (a,b) HA was detected with biotinylated HA binding protein
(HAbP) and FastRed development giving purple-red staining for HA.
Counterstain was performed with hematoxylin. The tumor cells (T) express
less HA compared with the surrounding stromal fibroblasts (Fbs). Inserted
picture in a: tissue staining after pre-treatment with hyaluronidase.
(c) Fluorescence image of the same biopsy with HAbP-biotin detected
by streptavidin-488 and anti-CD90 detected by goat-anti mouse-Cy3.
The nuclei were counterstained with 4,6-diamidino-2-phenylindole.
Again, stroma areas rich with Fbs (red) contain more HA than the tumor.
(d) Streptavidin-488 control without HAbP and isotype control for anti-CD90.
Bar¼50 mm. (e) In vitro HA is released predominantly by Fbs (n¼ 4), and
(f) Fbs express significantly more HAS2–mRNA than MM (n¼ 5). P-values
were calculated using unpaired t-test. Data are presented as mean±SD.
*Po0.05 and **Po0.005. CM, conditioned medium; Fb-CM, Fb-conditioned
medium.
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HA-inducing potential did not vary (Supplementary Figure
S1a online), thus being excluded as potential inductor.
Second, Bro-CM was treated with trypsin beads to degrade
proteins, verified by Coomassie staining (Supplementary
Figure S1b online). Fbs incubated with protein-depleted
Bro-CM did not show increased HAS–mRNA compared with
untreated Bro-CM (Supplementary Figure S1c and d online),
suggesting that proteins might be responsible for upregulation
of HA synthesis in Fbs.
Melanoma-derived TGF-b1 has significant effects on
HAS1–mRNA, but not on the net HA synthesis by Fbs
Transforming growth factor (TGF)-b1 was reported to
stimulate HA synthesis in different cell types (Sugiyama
et al., 1998; Campo et al., 2007; Dai et al., 2007; Meran
et al., 2007). Here, recombinant TGF-b1 enhanced HAS1–
and HAS2–mRNA expression in Fbs and increased HA
production by B30% (Supplementary Figure S2a online).
TGF-b1 was released from Bro- and HT144-CM (Bro:
140.2±38.8 pgml1, HT144: 153.9±97.8 pgml1 per 105
cells), but was barely detectable in A375-CM (o30 pgml1),
which is in accordance with HA-inducing properties of these
cell lines. Silencing of TGF-b1 with small interfering RNA
(siRNA) in Bro and HT144 melanoma cells decreased TGF-b1
by about 90% in the resulting MM-CM (Supplementary Figure
S2b online). Fbs were exposed to these TGF-b1-reduced MM-
CM. The inductive effect of MM-CM on HAS1–mRNA in Fbs
was significantly diminished with TGF-b1-reduced MM-CM
compared with scrambled control (Supplementary Figure S2c
online). In contrast, TGF-b1-reduced Bro-CM did not affect
HAS2–mRNA induction, whereas TGF-b1-reduced HT144-
CM partially lost its stimulatory capacity for HAS2 (Supple-
mentary Figure S2c online). Most importantly, however,
TGF-b1-reduced MM-CM still stimulated net HA synthesis by
Fbs significantly (Supplementary Figure S2d online). These
data suggest that despite the influence of TGF-b1 on HAS1
and, in part, on HAS2–mRNA in one cell line HT144, net HA
synthesis in dermal Fbs is controlled by other MM-derived
mediators in our experimental setting.
Melanoma-derived growth factors induce HAS2–mRNA and HA
synthesis in Fbs by the PI3/MAP-kinase pathway
As HAS2 appears not to be regulated by TGF-b1, we
investigated other putative mediator proteins. To identify
promising candidates we first analyzed the signaling
pathways involved focusing on the phosphatidylinositol
3/mitogen-activated protein (PI3/MAP)-kinase pathway.
Addition of PI3-kinase inhibitor LY294002 or the MEK1/2
inhibitor U0126 to Fb cultures reduced the stimulating
capacity of Bro-CM on HAS2–mRNA in Fbs (Figure 3a
and b), resulting in a clearly diminished HA release (Figure 3c
and d). HAS1–mRNA expression was not affected (data not
shown). This confirmed HAS2 as the major HA-synthesizing
enzyme in dermal Fbs, whose expression is controlled by the
PI3/MAP-kinase pathway.
Comparative analysis of growth factor expression in melanoma
cell lines
To identify the soluble factors released by MM responsible for
stimulating HA synthesis in Fbs in a PI3/MAP-kinase-
dependent manner, we took advantage of different capacities
of MM cell lines to induce HA in Fbs, i.e., strongly HA-
inducing Bro-MM and weakly HA-inducing A375-MM
(Figure 2e). We performed a growth factor array, comparing
strongly HA-inducing Bro-CM with weakly HA-inducing
A375-CM. On this array we found PDGF-AA to be the
most prominent growth factor in Bro-CM, which was
expressed about six times more compared with A375-CM
(Figure 4a and b). As PDGFs function through the PI3/MAP-
kinase pathway, and different members of the PDGF family
have been suggested to induce HA synthesis (Godden et al.,
1999), we also analyzed PDGF-AB and PDGF-BB expression
on this array. These proteins were barely detectable in both
cell lines, although levels in Bro-CM always exceeded those
in A375-CM (Figure 4a and b). PDGF-CC, a more recently
discovered member of the PDGF family (Anderberg et al.,
2009), was not covered by the growth factor array. Instead,
we analyzed PDGF-C–, as well as PDGF-A–, and PDGF-
B–mRNA by quantitative RT-PCR, including a second strongly
HA-inducing melanoma cell line HT144. We found PDGF-A–
and PDGF-C–mRNA to be significantly higher expressed in
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Figure 2. Fibroblast-derived hyaluronan (HA) stimulates malignant
melanoma (MM) proliferation. MM-derived mediators stimulate hyaluronan
synthase 2 (HAS) expression and HA synthesis in fibroblasts. (a) Bro
proliferation was assayed in fibroblast-conditioned medium (Fb-CM) of
control fibroblasts, fibroblasts transfected with scrambled control (scr), and
HAS2-silenced fibroblasts (n¼ 4). Proliferation of Bro cells alone was set to
100%. (b) The silencing of HAS2–mRNA results in significant reduction of
HA content in the corresponding FB-CM (n¼ 8). P-values were calculated
using unpaired t-test. (c, d) Dermal fibroblasts were exposed to MM-CM.
Fibroblasts were harvested after 3 hours for quantitative reverse
transcription-PCR of (c) HAS1– and (d) HAS2–mRNA (A375-CM (n¼ 3);
Bro- and HT144-CM (n¼ 5). (e) After 24 hours incubation with MM-CM,
HA was quantified in Fb-CM (n¼ 7). P-values were calculated using
Wilcoxon signed rank-sum test. Data are presented as mean±SD.
*Po0.05, **Po0.005, and ***Po0.0005.
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HA-inducing Bro- and HT144-MM compared with A375-MM
(Figure 4c). PDGF-B–mRNA was expressed at minimal levels
in Bro cells only, which was in line with the array results
(Figure 4c).
Melanoma-derived PDGF-AA and PDGF-CC induce
HAS2–mRNA and HA synthesis in dermal Fbs
Next we silenced PDGF-A–and PDGF-C–mRNA in MM using
siRNA. Target mRNAs and detectable PDGF-AA protein were
reduced by 80–90% at 72 hours after transfection (Supple-
mentary Figure S3 online). Interestingly, PDGF-A silencing
led to increased PDGF-C–mRNA expression and vice versa
(Supplementary Figure S3a–d online), resulting in a sustained
HAS2 induction in Fbs (data not shown). Therefore, we
performed PDGF-A/PDGF-C double knockdown (Supple-
mentary Figure S3a online). PDGF-AA/CC-reduced MM-CM
showed diminished ability to induce HAS2–mRNA expres-
sion in Fbs (Figure 5a), and HA concentrations in super-
natants of exposed Fbs were decreased by 15–30% compared
with scrambled control (Figure 5b).
PDGF-AA and PFGF-CC both signal through PDGFR-a
(Fredriksson et al., 2004; Anderberg et al., 2009). Therefore,
we used neutralizing antibodies against PDGFR-a on Fbs.
Compared with isotype control, HAS2–mRNA induction
(Figure 5c) and HA release (Figure 5d) decreased significantly
in these Fbs, indicating that PDGFR-a signaling is involved
in Fb HA synthesis induced by MM-CM. Interestingly,
HAS1–mRNA in the exposed Fbs was not affected by these
inhibitions of the PDGFR-a signaling pathway, indicating
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Figure 3. Inhibition of the phosphatidylinositol 3/mitogen-activated protein
(PI3/MAP)-kinase pathway in fibroblasts leads to decreased stimulation
of hyaluronan synthase 2 (HAS2)–mRNA and hyaluronan (HA) synthesis
through malignant melanoma-conditioned medium (CM). Blocking of
the growth factor signaling way was carried out using the MAP/ERK-kinase
1/2 inhibitor U0126 and the PI3-kinase inhibitor LY294002. Fibroblasts
were incubated in duplicates with Bro-CM, Bro-CMþ10 mM U0126, or
Bro-CMþ 20 mM LY294002. Equivalent DMSO volumes were added to
serum-free medium as control. (a, b) HAS2–mRNA in fibroblasts was
analyzed after 3 hours incubation by quantitative reverse transcription-PCR.
(c, d) HA concentration in fibroblast supernatants was measured after
24 hours by ELISA. Data are presented as mean±SD.
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Figure 4. Comparative analysis of growth factor expression in three different
malignant melanoma (MM) cell lines. (a) Growth factor arrays were
performed to compare platelet-derived growth factor (PDGF)-AA, PDGF-AB,
and PDGF-BB in weakly stimulating A375-conditioned medium (CM) and
strongly stimulating Bro-CM. A typical membrane is shown with the
PDGF spots indicated. PP: positive controls. (b) Relative protein signals on the
arrays were measured as optical density of chemiluminescence (n¼ 2).
(c) PDGF-A–, PDGF-B–, and PDGF-C–mRNA in three different MM were
analyzed by quantitative reverse transcription-PCR (n¼ 5). P-values were
calculated using the unpaired Student’s t-test. Data are presented as
mean±SD. **Po0.005 and ***Po0.001. IOD, integrated optical density.
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that HAS2 is the main target of PDGF-AA/-CC containing
MM-CM (Supplementary Figure S4 online).
DISCUSSION
Tumor–stroma interactions are essential for progression and
metastasis of solid tumors (Kalluri and Zeisberg, 2006;
Ostman and Augsten, 2009). Stroma cells provide a tissue
scaffold allowing tumor growth and dissemination. Tumor
cells modify the matrix synthesizing and degrading capacities
of stroma cells by direct and paracrine interactions. Here we
show that melanoma cells increase HA synthesis in dermal
Fbs through soluble proteins, and that Fb-derived HA
promotes MM proliferation in vitro.
In situ examination of MM by Karjalainen et al. (2000) had
shown strong staining of HA in the tumor stroma, whereas the
tumor itself varied in HA expression levels as found in a large
cohort of stage I melanomas. In the MM biopsies analyzed
here we detected stronger HAbP binding in the adjacent
dermal stroma compared with the tumor, suggesting that HA
was deposited by the Fbs, which were also detected in these
HA-containing regions. The impact of infiltrating inflamma-
tory cells cannot be ruled out by this data; however, HA was
also abundant in the stroma when only little infiltrate was
present (data not shown). Indeed, we show that in vitro Fbs
outperform MM in regard to HA synthesis by more than the
factor 1,000. These data are supported by comparative
mRNA analyses of the HA-synthesizing enzyme HAS2, which
is significantly stronger expressed in Fbs than in MM. In
accordance with previous data (Gebhardt et al., 2010), the
two other known HASs HAS1 and HAS3 are only expressed
at low mRNA levels in both cell types. These findings suggest
that the majority of tumor-promoting stromal HA originates
from Fbs. Likewise, in breast cancer stromal Fbs are
considered to be responsible for HA accumulation (Itano
et al., 2008). In breast and prostate cancer, HA amount and
tumor aggressiveness correlate (Auvinen et al., 2000;
Lipponen et al., 2001). Stromal HA enhances tumor cell
invasion and motility (Afify et al., 2009) and HA diminishes
intercellular adhesion, thereby promoting cell migration
(Itano et al., 2002). HA has a pivotal role for proliferation
in different tumors (Ahrens et al., 2001; Edward et al., 2005;
Misra et al., 2008). Our own experiments confirmed an
enhanced MM proliferation depending on Fbs’ HA synthesis.
The silencing of HAS2 in Fbs strongly decreased their HA
synthesis, resulting in decreased MM cell proliferation.
Decreased HAS2 expression in silenced Fbs was not
compensated by an induction of HAS1 or HAS3 (data not
shown). Pre-treatment of Fb-CM with hyaluronidase removed
the detectable HA, and consequently the induction of MM
proliferation by these Fb-CM also decreased (data not
shown). Nevertheless, the low synthesis of tumor-cell–asso-
ciated HA also provides crucial benefits for the tumor itself,
as shown by gain-of-function (Ichikawa et al., 1999; Kosaki
et al., 1999) or loss-of-function (Simpson et al., 2002;
Udabage et al., 2005; Li et al., 2007b) studies in several
tumor models. CD44 was shown to be the receptor on tumor
cells that is involved in the HA-mediated induction of cell
proliferation (Ahrens et al., 2001; Morrison et al., 2001;
Anderegg et al., 2009). Indeed, only the proliferation of CD44
expressing cell lines Bro and HT144 was increased by HA-
containing Fb-CM, whereas the proliferation of CD44-
negative MM cell line RPM-MC ((Hoashi et al., 2001;
Morrison et al., 2001; Anderegg et al., 2009) remained
unchanged (data not shown).
MMs are able to elevate HA synthesis in Fbs, which has
been shown before (Knudson et al., 1984; Merrilees and
Finlay, 1985; Godden et al., 1999; Edward, 2001).
The stimulation of HA synthesis by MM-CM can depend
on the glucose content in the medium; specifically, low
glucose levels (1.0mgml1) in MCCM were superior in
inducing HA (Edward et al., 2005). The MM-CM used here
contained 0.38±0.13mgml1 glucose when they were
transferred to Fbs. Low glucose levels have been shown not
to affect the HA release of Fbs during short-term incubations,
similar to those used in this study (Cechowska-Pasko and
Bankowski, 2010). Thus, under low glucose conditions used
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Figure 5. Silencing of platelet-derived growth factor (PDGF)-A– and PDGF-
C–mRNA in malignant melanoma (MM) or blocking of PDGFR-a on
fibroblasts reduces hyaluronan synthase 2 (HAS2)–mRNA induction and
hyaluronan (HA) release from exposed fibroblasts. PDGF-A and PDGF-C
silencing was performed in Bro- and HT144-MM (Supplementary Figure S3
online). Fibroblasts were exposed to the resulting MM-conditioned medium
(CM). (a) HAS2–mRNA was quantified by quantitative reverse transcription
(RT)-PCR after 6 hours of incubation. The results are presented as percent of
serum-free control (n¼3). (b) HA concentration in fibroblast supernatants
was measured by ELISA after 24 hours with MM-CM (n¼ 3). (c, d) Fibroblasts
were pre-incubated with neutralizing antibody against PDGFR-a or mouse-
isotype control before MM-CM was added. As controls, isotype incubation
(set to 100%) and incubation of fibroblasts with aPDGFR-a alone
(black column) were used. (c) HAS2–mRNA was quantified by RT-PCR
after 3 hours. Results are presented as percent of serum-free control (n¼3).
(d) HA concentration in fibroblast supernatants was measured after
24 hours by ELISA (n¼ 3). Data are presented as mean±SD. *Po0.05,
**Po0.005; Student’s paired t-test.
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here only the growth factors within the MM-CM are expected
to modify HA synthesis of Fbs.
We found induction of HAS1– and HAS2–mRNA tran-
scription in Fbs exposed to Bro-CM and HT144-CM, but not
A375-CM. This enabled us to identify the soluble factors from
MM involved in HA induction in Fbs. Lactate, previously
described as an inductor of HA synthesis (Stern et al., 2002),
was excluded, as lactate concentrations in MM-CM did not
correlate with their HA-stimulating potential, which was
however trypsin-sensitive indicative of a protein mediator.
Indeed, HA synthesis can be induced by proteins such as
IL-1b, TNFa (Campo et al., 2006), TGF-b1 (Meran et al.,
2007), or PDGF-BB (Li et al., 2007a) via induction of
transcription of HASs. However, the effectiveness of the
cytokines may differ in various cell types (Kennedy et al.,
2000; Ducale et al., 2005; Meran et al., 2007). Additionally,
HAS activity may also be regulated by posttranslational
modifications such as phosphorylation (Vigetti et al., 2009)
and ubiquitination (Karousou et al., 2010).
In our experiments, recombinant TGF-b1 increased HA
synthesis in dermal Fbs by induction of HAS1– and
HAS2–mRNA. TGF-b1 concentrations in MM-CM matched
the HA-stimulatory capacity of MM, so we initially focussed
on MM-derived TGF-b1 as potential mediator. When silen-
cing TGF-b1 expression in MM, the resulting TGF-b1-reduced
MM-CM failed to induce HAS1–mRNA expression, whereas
HAS2–mRNA expression was differently affected in the
inducing MM cell lines. Obviously, TGF-b1 has a predomi-
nant influence on HAS1 expression as reported earlier
(Stuhlmeier and Pollaschek, 2004). However, net HA release
by Fbs did not decrease. The major HA-synthesizing enzyme
in Fbs is HAS2 (Averbeck et al., 2007), and although TGF-b1
cannot be completely ruled out as a HAS2–mRNA inductor
referring to earlier reports (Heldin et al., 1989; Sugiyama
et al., 1998), other MM-derived factors seem to compensate a
lack of TGF-b1. These findings are in line with the study by
Godden et al. (1999) when blocking TGF-b with an antibody
also was not effective in reducing induction of HA synthesis.
Blocking experiments revealed the involvement of PI3/MAP-
kinase signaling in HAS2 induction in Fbs.
Various growth factors function through PI3/MAP-kinase
pathway, including PDGF. Godden et al. (1999) demon-
strated that PDGFR-a was phosphorylated in Fbs after
exposure to MM-CM, and proposed PDGF-AA, PDGF-AB,
and PDGF-BB as key inductors of the increased HA synthesis.
We could confirm this for PDGF-AA, but could not
demonstrate a role for PDGF-AB and PDGF-BB. When
comparing growth factor release from strongly HA-inducing
Bro-MM and weakly HA-inducing A375-MM, PDGF-AA was
identified as the most probable factor to induce HAS2 in Fbs.
We also suspected PDGF-CC, a more recently discovered
member of the PDGF family (Li and Eriksson, 2003), to be
involved. PDGF-CC was reported to be an MM-derived
stimulator of osteopontin in stromal Fbs (Anderberg et al.,
2009). We found by mRNA analysis that expression patterns
of PDGF-A and PDGF-C matched the HA-inducing properties
of the respective cell lines, while PDGF-B was barely
detectable in all MM.
However, individual silencing of PDGF-A– or PDGF-
C–mRNA in Bro- and HT144-MM had no effect on HA
synthesis in Fbs. Interestingly, PDGF-AA and PDGF-CC seem
to compensate for each other, as silencing of one mRNA led
to significantly increased expression of the other. Double
knockdown of PDGF-A/PDGF-C in MM clearly reduced
HAS2–mRNA induction, but reduced HA synthesis by Fbs at
best by 30%, which is most likely to residual PDGF-AA or
PDGF-CC. The remaining concentrations of PDGF-AA
measured in MM-CM have been shown earlier to contribute
to induced HA synthesis in Fbs (Heldin et al., 1989).
As another approach to test the role for melanoma-derived
PDGF-AA and PDGF-CC in inducing HA release from Fbs,
we blocked PDGFR-a—the receptor for both PDGF-AA and
PDGF-CC (Fredriksson et al., 2004; Anderberg et al., 2009).
Indeed, pre-incubation of Fbs with neutralizing antibodies
against PDGFR-a reduced HAS2–mRNA induction as well as
significantly diminished HA synthesis in Fbs.
This confirmed PDGF-AA and PDGF-CC as key MM-
derived factors to induce HA synthesis via HAS2 induction in
Fbs. As HAS1 was not affected by blocking PDGFR-a
signaling, we conclude that HAS2 is the main target of
MM-cell–derived PDGF-AA and PDGF-CC. Although PDGF-
Ra blocking reduced HA production by more than 50%, we
expect that other MM-derived soluble factors might function
synergistically with PDGF-AA and PDGF-CC in stimulating
HA synthesis in Fbs.
Taken together, we demonstrated that MM are able to
induce HA synthesis in pertitumoral dermal Fbs via induction
of HAS2. This is controlled by the release of soluble proteins
from MM, especially PDGF-AA and PDGF-CC. HA synthe-
sized by dermal Fbs in turn stimulates MM proliferation. This
supports the notion that in MM the interaction of tumor cells
with stromal Fbs regulates local HA metabolism, which is of
role in tumor progression.
MATERIALS AND METHODS
Cell culture
Primary Fb cultures obtained by outgrowth from skin biopsies and
melanoma cell lines Bro (kindly provided by Dr J Eberle Berlin;
Lockshin et al. (1985)), HT144 (kindly provided by Dr van Muijen;
van Muijen et al. (1995)) and A375 (ATCC-CRL1619) were cultured
in 1:1 mix of RPMI-1640 and DMEM (Biochrom, Berlin, Germany)
supplemented with 10% fetal calf serum (PAA, Pasching, Austria),
Penicillin/Streptomycin (Biochrom) and Mycokill (PAA). All cells
were maintained at 37 1C in a humidified 5% CO2 atmosphere. To
generate CM, cells were washed with phosphate-buffered saline and
incubated with serum-free 1:1 mix of RPMI-1640 and DMEM for
24 hours. The medium contained 1.5mgml1 glucose. CM was
harvested, centrifuged and stored at 80 1C until use. The CM was
not concentrated, used without additional nutrition and contained
0.38±0.13mgml1 glucose. Cell numbers were determined using
the Countess device (Invitrogen, Karlsruhe, Germany). Before experi-
ments, MM and Fbs between passages 3–6 were washed with
phosphate-buffered saline and maintained in serum-free 1:1 mix of
RPMI-1640 and DMEM to synchronize cell cycle over night.
Medium transfer experiments were performed by exposing Fbs or
MM monolayer cultures to CM for 3 hours to analyze mRNA or
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24 hours for HA measurements. Fbs were stimulated with 10 ngml1
TGF-b1 (Strathman Biotech, Hamburg, Germany) for 3 hours to
analyze mRNA or for 24 hours for HA measurements.
Proliferation assays
Serum-starved MM cells (1.6 104 in 150 ml DMEM with 4% fetal
calf serum) were mixed with 500 ml DMEM (4% fetal calf serum)
or with 500ml Fb-CM and splitted in 4 wells (150 ml each) of black
96-well plates (Nunc, Roskilde, Denmark). After 20 hours, BrdU
was added for 4 hours and proliferation was measured by BrdU-
chemiluminescence ELISA (Roche, Mannheim, Germany), according
to the manufacturer’s protocol.
SiRNA transfection of MM
SiRNA (Stealth Select RNAi) specific for TGF-b1 (Stealth Select RNAi
HSS110683 and HSS110684) and scrambled siRNA (Stealth RNAi
Negative Control (High and Medium GC) were purchased from
Invitrogen. MMs were transfected with either 40 pmolml1 gene-
specific siRNA or 40pmolml1 scrambled control siRNA using
Lipofectamine (RNAiMax, Invitrogen), according to the manufac-
turer’s instructions. After 48 hours, TGF-b1–mRNA was quantified by
RT-PCR. TGF-b1 concentrations in MM-CM were measured by ELISA
(R&D Systems, Minneapolis, MN). SiRNA specific against PDGF-A
(ON-TARGETplusSMARTpool L-013154-01-0010), PDGF-C (ON-
TARGETplusSMARTpool L-011748-00-0010), and negative control
(On-TARGETplus Non-Target; Dharmacon, Lafayette, CO) were
purchased from Fisher Scientific (Schwerte, Germany). Transfection
was performed as described above. PDGF-A– and PDGF-C–mRNA
were measured after 72 hours by quantitative RT-PCR. Silencing of
MM was achieved without eliciting critical stress–responses con-
firmed by quantitative RT-PCR of the stress gene 20–50 oligoadenylate
synthetase (Sledz et al., 2003).
SiRNA transfection of Fbs
SiRNA specific for HAS2 and HAS2, as well as scrambled siRNA
were purchased from Ribbox (Radebeul, Germany). Sequences
are provided in Supplementary Table S1 online. 2.25 104
Fbs per well were transfected with either 5–20 nM of gene-specific
siRNA or 5–20 nM of scrambled control siRNA using ribboxxFECT
(Ribbox), according to the manufacturer’s instructions. After
36 hours, transfection medium was replaced by DMEM containing
4% fetal calf serum (0.6ml per well of a 24-well plate). This
medium was harvested after 24 hours of incubation. At this time
point, HA content was determined and these Fb-CMs were used
for cell proliferation assays. Fbs were used for quantitation of
HAS mRNA.
Blocking experiments
MM-CM was incubated with immobilized Trypsin (Pierce, Rockford)
according to the manufacturer’s instructions. Fbs were incubated in
parallel with MM-CM or trypsin-treated MM-CM for 3 hours.
Inhibition of PI3/MAP-kinase pathway was performed using
MAPK/ERK kinase 1/2 10 mM inhibitor U0126 and PI3K inhibitor
LY294002 (both Calbiochem, Darmstadt, Germany) by simulta-
neously incubating Fbs with MM-CM, MM-CMþ U0126, or MM-
CMþ 20 mM LY294002 for 3 hours and 24 hours. Fbs were exposed
to CM of siRNA-transfected MM for 3 hours or 6 hours to analyze
mRNAs and 24 hours to determine HA concentrations.
Neutralization experiments were performed by pre-incubating
Fbs with 10 mgml1 anti-PDGFR-a (R&D Systems) or normal mouse-
IgG (isotype control, R&D Systems) before exposure to MM-CM for
3 hours and 24 hours.
RNA preparation and complementary DNA synthesis
RNA preparation and complementary DNA synthesis were per-
formed as described (Anderegg et al., 2009). Primer pairs for
quantitative RT-PCR were designed using HUSAR software (EMBL,
Heidelberg, Germany) and are indicated in Supplementary Table S1
online. Quantitative RT-PCR was performed as described (Anderegg
et al., 2009; Gebhardt et al., 2010).
Immunoaffinity staining for HA
The study was conducted according to the Declaration of Helsinki
Principles.
HA staining of MM biopsy for HA with biotinylated HAbP
(Seikagaku, Tokyo, Japan) including the pre-treatment of sections
with hyaluronidase for control of specific HAbP binding were
performed as described (Averbeck et al., 2007).
Second, double stainings were performed with HAbP (Seikagaku)
and the anti-CD90 antibody AS02, which detects Fbs and activated
microvascular endothelium (Saalbach et al., 1997). HAbP was
visualized with Streptavidin-488 (Mobitec, Goettingen, Germany)
and bound CD90 was detected by goat-anti mouse-Cy3 (Dianova,
Hamburg, Germany).
HA-ELISA
HA concentrations were measured by ELISA (Corgenix, Broomfield,
CO) following the manufacturer’s protocol. Samples were assayed as
duplicates and cell numbers were determined after sampling. All HA
concentrations were normalized to cell counts.
Growth factor array and ELISA
Expression of growth factors in A375- and Bro-CM was analyzed
using RayBio Human Growth Factor Antibody Array 1 Map
(RayBiotech, Norcross, GA) according to the manufacturer’s
instruction. Data from two different MM-CM were used from each
cell line. PDGF-AA was measured by ELISA (Raybiotech) according
to the manufacturers’ recommendations.
Statistical analysis
Data are expressed as mean±SD. Statistical analysis was performed
with GraphPad Prism 4 (GraphPad Software, La Jolla, CA) using
unpaired t-test, paired t-test, or Wilcoxon sign-rank test.
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